In November 1979 Dr Lane proposed a scheme that allowed regions to receive their concentrate and albumin in proportion to the yield from the plasma they had sent to BPL. He argued that that would provide regions with a meaningful link to BPL and would incentivise and improve the plasma collection system. Read more about In November 1979 Dr Lane proposed a scheme that allowed regions to receive their concentrate and albumin in proportion to the yield from the plasma they had sent to BPL. He argued that that would provide regions with a meaningful link to BPL and would incentivise and improve the plasma collection system.
The estimate of £6-7 million put a stop to any further discussions with Scotland regarding plans for the redevelopment of BPL and was described by Dr Walford as "a sort of bitter blow". Read more about The estimate of £6-7 million put a stop to any further discussions with Scotland regarding plans for the redevelopment of BPL and was described by Dr Walford as "a sort of bitter blow".
Dr Walford described the delays between April 1979, when the Medicines Inspectorate conducted their inspection and condemned the premises operated for BPL as unsuitable for a pharmaceutical company, and the middle of May 1983, when construction began as "unconscionable". Read more about Dr Walford described the delays between April 1979, when the Medicines Inspectorate conducted their inspection and condemned the premises operated for BPL as unsuitable for a pharmaceutical company, and the middle of May 1983, when construction began as "unconscionable".
Dr Walford described the process in deciding to develop BPL as "totally chaotic, protracted and difficult" and "needlessly so". Read more about Dr Walford described the process in deciding to develop BPL as "totally chaotic, protracted and difficult" and "needlessly so".
Regional health authorities were described by Dr Walford as "fiefdoms". Read more about Regional health authorities were described by Dr Walford as "fiefdoms".
Dr Walford said that Dr Lane was right to describe the difficulties in meeting the problems of the NBTS as having been "accentuated by the growth in requirement during the 1970s of plasma products, an exercise in production maintained without adequate planning, co-ordination or finance from the outset." Read more about Dr Walford said that Dr Lane was right to describe the difficulties in meeting the problems of the NBTS as having been "accentuated by the growth in requirement during the 1970s of plasma products, an exercise in production maintained without adequate planning, co-ordination or finance from the outset."
A special health authority was established to take responsibility for the management of the BPL, the PFL in Oxford and the Blood Reference Group Laboratory. Read more about A special health authority was established to take responsibility for the management of the BPL, the PFL in Oxford and the Blood Reference Group Laboratory.
Dr Walford remembered her frustration about "innumerable and repetitive meetings which generally ended without moving matters forward to any appreciable extent." Read more about Dr Walford remembered her frustration about "innumerable and repetitive meetings which generally ended without moving matters forward to any appreciable extent."
Dr Vaughan announced that there would be "no commercial management of Blood Products Laboratory: modernisation programme already underway." Read more about Dr Vaughan announced that there would be "no commercial management of Blood Products Laboratory: modernisation programme already underway."
Dr Walford described the Deputy CMO, Dr Harris, as "exasperated" because of the Ministers decision to defer the eventual decision on whether to build a new laboratory within the NHS. Read more about Dr Walford described the Deputy CMO, Dr Harris, as "exasperated" because of the Ministers decision to defer the eventual decision on whether to build a new laboratory within the NHS.